Molecularly targeted therapies in locally advanced non-small-cell lung cancer

Siddhartha Devarakonda; Daniel Morgensztern; Ramaswamy Govindan

doi:10.1016/j.cllc.2013.03.005

Molecularly targeted therapies in locally advanced non-small-cell lung cancer

Siddhartha Devarakonda, Daniel Morgensztern, Ramaswamy Govindan

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Approximately a third of the patients with non-small cell lung cancer (NSCLC) present with locally advanced disease not amenable to curative resection. Concurrent chemoradiation is currently the treatment of choice for these patients. Outcomes in patients with locally advanced NSCLC treated with concurrent chemoradiation are modest at best. No significant progress has been made over the past decade in this subset of patients with NSCLC. Several trials have examined the role of molecular targeted therapies in this setting. We review the results of these trials and present the outline of a proposed prospective clinical trial to evaluate targeted drugs in molecularly selected group of patients with locally advanced NSCLC.

Original language	English
Pages (from-to)	467-472
Number of pages	6
Journal	Clinical Lung Cancer
Volume	14
Issue number	5
DOIs	https://doi.org/10.1016/j.cllc.2013.03.005
State	Published - Sep 2013

Keywords

Concurrent chemoradiation
Locally advanced NSCLC
NSCLC
Targeted therapy

Access to Document

10.1016/j.cllc.2013.03.005

Cite this

@article{3eed7325ecb54a26acd0f45225b14514,

title = "Molecularly targeted therapies in locally advanced non-small-cell lung cancer",

abstract = "Approximately a third of the patients with non-small cell lung cancer (NSCLC) present with locally advanced disease not amenable to curative resection. Concurrent chemoradiation is currently the treatment of choice for these patients. Outcomes in patients with locally advanced NSCLC treated with concurrent chemoradiation are modest at best. No significant progress has been made over the past decade in this subset of patients with NSCLC. Several trials have examined the role of molecular targeted therapies in this setting. We review the results of these trials and present the outline of a proposed prospective clinical trial to evaluate targeted drugs in molecularly selected group of patients with locally advanced NSCLC.",

keywords = "Concurrent chemoradiation, Locally advanced NSCLC, NSCLC, Targeted therapy",

author = "Siddhartha Devarakonda and Daniel Morgensztern and Ramaswamy Govindan",

year = "2013",

month = sep,

doi = "10.1016/j.cllc.2013.03.005",

language = "English",

volume = "14",

pages = "467--472",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

number = "5",

}

TY - JOUR

T1 - Molecularly targeted therapies in locally advanced non-small-cell lung cancer

AU - Devarakonda, Siddhartha

AU - Morgensztern, Daniel

AU - Govindan, Ramaswamy

PY - 2013/9

Y1 - 2013/9

N2 - Approximately a third of the patients with non-small cell lung cancer (NSCLC) present with locally advanced disease not amenable to curative resection. Concurrent chemoradiation is currently the treatment of choice for these patients. Outcomes in patients with locally advanced NSCLC treated with concurrent chemoradiation are modest at best. No significant progress has been made over the past decade in this subset of patients with NSCLC. Several trials have examined the role of molecular targeted therapies in this setting. We review the results of these trials and present the outline of a proposed prospective clinical trial to evaluate targeted drugs in molecularly selected group of patients with locally advanced NSCLC.

AB - Approximately a third of the patients with non-small cell lung cancer (NSCLC) present with locally advanced disease not amenable to curative resection. Concurrent chemoradiation is currently the treatment of choice for these patients. Outcomes in patients with locally advanced NSCLC treated with concurrent chemoradiation are modest at best. No significant progress has been made over the past decade in this subset of patients with NSCLC. Several trials have examined the role of molecular targeted therapies in this setting. We review the results of these trials and present the outline of a proposed prospective clinical trial to evaluate targeted drugs in molecularly selected group of patients with locally advanced NSCLC.

KW - Concurrent chemoradiation

KW - Locally advanced NSCLC

KW - NSCLC

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84883749760&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2013.03.005

DO - 10.1016/j.cllc.2013.03.005

M3 - Review article

C2 - 23684057

AN - SCOPUS:84883749760

SN - 1525-7304

VL - 14

SP - 467

EP - 472

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 5

ER -

Molecularly targeted therapies in locally advanced non-small-cell lung cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this